Skip to main content
Clinical Trials/NCT02650921
NCT02650921
Completed
Not Applicable

A Randomized, Evaluator Blinded, Split-hand Study to Evaluate the Effectiveness and Safety of Restylane Lyft With Lidocaine Compared to no Treatment for Injection in the Dorsal Hand to Correct Volume Deficit

Galderma R&D0 sites92 target enrollmentDecember 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Volume Deficit in the Hand
Sponsor
Galderma R&D
Enrollment
92
Primary Endpoint
Responder Rate Using Validated Hand Grading Scale
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This is a randomized, evaluator-blind, split hand, multi-center study of the effectiveness and safety or Restylane Lyft with Lidocaine compared to no treatment for injection in the dorsal hand to correct volume deficits.

Registry
clinicaltrials.gov
Start Date
December 2015
End Date
December 2016
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects willing to comply with the requirements of the study and providing a signed written informed consent including release of copyright of hand images.
  • Males or females, 22 years of age or older
  • Willing and able to perform hand functionality tests .

Exclusion Criteria

  • History of allergy or hypersensitivity to injectable HA gel or to gram positive bacterial proteins.
  • History of allergy or hypersensitivity to lidocaine or other amide type anesthetics.
  • Previous hand surgery including sclerotherapy, or history of hand trauma.
  • Advanced photo aged/ photo damaged skin or skin condition with very crinkled or fragile skin on the dorsal hands.

Outcomes

Primary Outcomes

Responder Rate Using Validated Hand Grading Scale

Time Frame: 12 Weeks

A responder is defined as a hand with at least one improvement from baseline.

Secondary Outcomes

  • Question 12 From Subject Satisfaction Questionnaire(Week 12)
  • Question 4 From Subject Satisfaction Questionnaire(Week 12)
  • Question 3 From Subject Satisfaction Questionnaire(Week 12)
  • Question 8 From Subject Satisfaction Questionnaire(Week 12)
  • Question 11 From Subject Satisfaction Questionnaire(Week 12)
  • Responder Rate Using Validated Hand Grading Scale(24 weeks)
  • Improvement in Hand as Evaluated by IPR(24 weeks)
  • GAIS by Treating Investigator(24 weeks)
  • Evaluate GAIS by Subjects(20 weeks)
  • Evaluate GAIS by Subject(24 weeks)
  • Question 2 From Subject Satisfaction Questionnaire(Week 12)
  • Question 7 From Subject Satisfaction Questionnaire(Week 12)
  • Question 9 From Subject Satisfaction Questionnaire(Week 12)
  • Question 10 From Subject Satisfaction Questionnaire(Week 12)
  • Question 6 From Subject Satisfaction Questionnaire(Week 12)
  • Question 1 From Subject Satisfaction Questionnaire(Week 12)
  • Question 5 From Subject Satisfaction Questionnaire(Week 12)
  • Question 13 From Subject Satisfaction Questionnaire(Week 12)

Similar Trials